Sign In
Buy HRMY
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
12:03pm, Sunday, 17'th Dec 2023
With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital
Russell 2000 Front-Runners: 3 Stocks to Keep an Eye On
08:53pm, Thursday, 07'th Dec 2023
While all eyes may be on the usual suspects of market hype and influence, astute investors with a contrarian streak may want to consider Russell 2000 stocks. A key benchmark for the vitality of up-and
PLYMOUTH MEETING, Pa. , Dec. 5, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializin
HRMY vs. REGN: Which Stock Is the Better Value Option?
12:47pm, Tuesday, 21'st Nov 2023
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two s
How Much Upside is Left in Harmony Biosciences Holdings, Inc. (HRMY)? Wall Street Analysts Think 76.62%
11:17am, Monday, 13'th Nov 2023
The mean of analysts' price targets for Harmony Biosciences Holdings, Inc. (HRMY) points to a 76.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, stro
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
11:17am, Wednesday, 08'th Nov 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
12:47pm, Friday, 03'rd Nov 2023
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks is mor
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS ON OCTOBER 31, 2023
08:05am, Tuesday, 17'th Oct 2023
PLYMOUTH MEETING, Pa. , Oct. 17, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializ
Harmony Stock Tanks On Study Miss For Narcolepsy Drug: Problems May Be Escalating
04:01pm, Friday, 13'th Oct 2023
Harmony Biosciences' only product, WAKIX - pitolisant - has generated over $1 billion in net revenue since its launch. The company's Q2 2023 earnings showed a 39.6% growth in net product revenues comp
Why Shares of Harmony Bioscience Are Falling on Friday
12:52pm, Friday, 13'th Oct 2023
Harmony has already gotten approval for the drug to treat adults with excessive daytime sleepiness who have narcolepsy. Harmony's second-quarter revenue was up 25%, year over year.
Harmony Biosciences stock drops on disappointing study results
11:29am, Friday, 13'th Oct 2023
Harmony Biosciences Holdings Inc shares sank 38% to $18.66 in late-morning trading on Friday after the pharmaceutical company reported topline results from the INTUNE study of pitolisant, which missed
2 Magnificent Growth Stocks to Buy Right Now
09:25am, Wednesday, 04'th Oct 2023
Growth stocks are an important element of a well-balanced portfolio. Ginkgo Bioworks and Harmony Biosciences are two risky growth plays that could deliver stellar returns over the long term.
Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep
02:16am, Sunday, 24'th Sep 2023
Harmony Biosciences has experienced strong and profitable growth following the approval and commercialization of WAKIX. The company's success has allowed for funding of other programs and acquisitions
HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE
08:05am, Wednesday, 13'th Sep 2023
PLYMOUTH MEETING, Pa. , Sept. 13, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializ
Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million
09:18am, Monday, 14'th Aug 2023
Shares of Zynerba Pharmaceuticals Inc. ZYNE, +0.89% jumped 300% premarket on Monday after Harmony Biosciences Holdings Inc. HRMY, -0.47% said it would acquire the cannabinoid therapy company in a deal
